The Phase 3 CLARIFY Trial With 64Cu-SAR-bisPSMA: A Next-Generation PSMA Imaging Agent

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
David Morris, MD, FACS, of Urology Associates of Nashville, discusses the emerging role of copper-based PSMA imaging agents, specifically Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA, in prostate cancer diagnostics. He highlights the unique dual-binding structure of this tracer, which may offer increased sensitivity and specificity compared to gallium-based PSMA tracers. The conversation explores the clinical benefits of same-day and next-day imaging, which allows for more flexible scheduling and may enhance detection of smaller nodal metastases.

#prostatecancer #urology #oncology #cancerresearch #cancer
Category
Urology
Be the first to comment

Up Next